RxDoctor Payments Data

Allison Lammoglia, APRN

Psychiatric/Mental Health · Kansas City, MONPI 1902661648

Payments from drug & device makers

$3,280in general payments, 2019–2025

Across 201 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$636
  • AbbVie$588
  • E.r. Squibb & Sons, L.L.C.$499
  • Teva Pharmaceuticals USA, Inc.$391
  • Alkermes, Inc.$377
  • Neurocrine Biosciences, Inc.$263
  • plus $527 from 6 others

What the payments were for

  • Food & beverage$3,20498%
  • Education$762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,280 in reported general payments places this provider in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$2,465
Medicare patients
15
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$44,766
RexultiBrexpiprazole25$40,957
LybalviOlanzapine/Samidorphan Malate16$24,933
Lurasidone Hcl14$4,231
Aripiprazole62$2,845
Paliperidone ErPaliperidone15$2,826
Bupropion XlBupropion Hcl76$1,919
Vilazodone Hcl21$1,903
Clozapine29$1,427
Hydroxyzine Hcl80$1,319
Hydroxyzine Pamoate30$1,182
Duloxetine Hcl43$902
Divalproex Sodium ErDivalproex Sodium14$839
Olanzapine23$649
Haloperidol20$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$68$44,76613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$636$40,95725 claims
Alkermes, Inc.Lybalvi$377$24,93316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →